Mr. Paul Duffy reports

AIML SUBSIDIARY NEURALCLOUD ENTERS STRATEGIC PARTNERSHIP WITH RKS MEDICAL TECHNOLOGIES TO ADVANCE CARDIOYIELD CLINICAL PILOTS

AI-ML Innovations Inc.'s wholly owned subsidiary, NeuralCloud Solutions Inc., has entered into a strategic partnership with RKS Medical Technologies, a Toronto-based medical technology company, to support clinical pilot deployments of NeuralCloud's CardioYield software platform with RKS Medical's myPatch Holter monitoring technology.

RKS Medical, a leading merger-and-acquisition advisory firm in the diagnostic imaging sector, also commercializes medical equipment and health care technology solutions across Canada and is the exclusive Canadian reseller of the myPatchSL wireless Holter recorder. The myPatchSL device is designed for patient and provider ease, offering lightweight, waterproof Holter monitoring with up to three channels of continuous ECG, multiple electrode size options, event markers, an internal clock, rechargeable battery and compatibility with major Holter analysis systems.

Under the partnership, RKS Medical is expected to introduce NeuralCloud to clinics using, or evaluating, myPatch technology to conduct preregulatory clearance pilot evaluations of CardioYield. The objective is to evaluate how CardioYield can support clinics by providing a software layer for enhanced ECG signal review, automated waveform analysis, report preparation and workflow efficiency using ECG recordings captured through myPatch devices.

Creating an integrated hardware and software workflow

The partnership is designed to create a more complete cardiac monitoring solution for clinics by pairing myPatch hardware with NeuralCloud's CardioYield software. myPatch provides the ECG recording hardware while CardioYield is intended to provide the software intelligence layer for reviewing and analyzing Holter recordings.

CardioYield is NeuralCloud's visualization and reporting platform powered by MaxYield, its proprietary ECG signal-processing engine. MaxYield is designed to improve ECG signal quality, isolate and label key waveform components -- including P waves, QRS complexes and T waves -- and extract beat-level interval data. CardioYield builds on those outputs by providing a user interface for reviewing enhanced Holter signals, highlighting PQRST intervals and morphology, grouping conditions and abnormalities, and generating structured Holter reports designed to support clinical workflow.

Esmat Naikyar, president of NeuralCloud and chief product officer of AI-ML, commented: "Clinics need cardiac monitoring solutions that are accurate, efficient and practical to deploy. RKS Medical's myPatch platform provides a flexible Holter recording option, and CardioYield is designed to add the software layer needed to transform ECG recordings into cleaner, structured and more actionable outputs. This partnership gives us a pathway to evaluate the combined workflow in real clinical environments."

Clinical pilot strategy

The initial focus of the partnership will be clinical pilot programs in Ontario, with potential expansion to additional Canadian provinces. RKS Medical is expected to help identify and introduce clinic sites while NeuralCloud will run the CardioYield pilots directly and handle clinical integration.

The pilot framework is expected to use deidentified ECG recordings captured through myPatch devices during normal care. The same ECG files are expected to be routed through both the clinic's existing workflow and CardioYield for side-by-side evaluation, allowing the parties to assess differences attributable to the software workflow.

Pilot evaluations are expected to assess physician-ready report agreement, false positives and false negatives, technician edit time, time to report, report quality, turnaround time, usability, total analyzable signal, artifact detection, signal quality scoring and detection of certain rhythm categories.

Paul Duffy, executive chairman and chief executive officer of AI-ML, added: "This partnership is about demonstrating CardioYield in the workflow where it matters: real clinics, real Holter files and real operational constraints. By working with RKS Medical and myPatch, we can evaluate CardioYield alongside an established Holter recording platform and show clinics how advanced ECG software may help improve throughput, signal quality and reporting efficiency."

Commercialization strategy

The partnership reflects NeuralCloud's broader strategy to build a network of clinical pilot sites and hardware partners ahead of future commercial deployment. By pairing CardioYield with myPatch technology, the company's objective is to offer clinics an integrated hardware and software pathway for Holter monitoring: one source recording, enhanced signal processing, structured review and report generation.

Ralph Schatzmair, president of RKS Medical Technologies, commented: "RKS Medical is focused on bringing practical medical technologies to Canadian health care providers. By working with NeuralCloud, we see an opportunity to evaluate an integrated myPatch and CardioYield workflow that may support clinics seeking efficient, high-quality Holter monitoring solutions."

CardioYield has not received Health Canada or Food and Drug Administration clearance, and is not currently authorized for diagnostic use. The proposed pilots are expected to be conducted as preregulatory clearance evaluations. During any pilot, the clinic's existing systems and qualified health care professionals will remain responsible for official reports, clinical interpretation and all patient care decisions. Nothing in the pilots or related evaluations constitutes a claim of Health Canada or FDA clearance, approval or authorization for CardioYield.

November, 2024, financing -- warrant expiry date extension

The company also announces that it has approved the extension of the expiry date of an aggregate of 44,189,076 existing share purchase warrants which were issued on Nov. 1, 2024, and Nov. 26, 2024, in conjunction with a non-brokered private placement of units at a price of 6.5 cents per unit. Each November, 2024, warrant is exercisable to acquire one common share of the company at an exercise price of 15 cents. The original expiry dates of the November, 2024, warrants are Nov. 1, 2026, in respect of 19,688,461 November, 2024, warrants, and Nov. 26, 2026, in respect of 24,500,615 November, 2024, warrants. The new expiry dates of the November, 2024, warrants are Nov. 1, 2029, and Nov. 26, 2029, respectively, a period of five years from the applicable issuance date.

All other terms and conditions of the November, 2024, warrants remain unchanged. The company notes that, pursuant to Canadian Securities Exchange Policy 6.7(3), amendments related to broker warrants are not permitted, and, as such, there is no extension to the broker warrants issued in conjunction with the November, 2024, financing. For further details with respect to the November, 2024, warrants or the November, 2024, financing, please refer to the press releases of the company dated Nov. 1, 2024, and Nov. 26, 2024, available on SEDAR+.

About AI-ML Innovations Inc.

AI-ML is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. Its proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights -- supporting earlier diagnosis, personalized treatment and more effective care.

AI-ML's shares trade on the Canadian Securities Exchange, the OTCQB Venture Market and the Frankfurt Stock Exchange.

We seek Safe Harbor.